#Morphine Market Report

[insightfulblogz]

Morphine Market Product Development Strategies by Prominent Players, 2032

Morphine is a powerful analgesic and one of the most widely used medications for managing severe pain, particularly in cases of post-surgical recovery, chronic pain, and cancer. As an opioid, morphine works by binding to opioid receptors in the brain, blocking pain signals and providing relief that allows patients to regain comfort and functionality. While it is highly effective, morphine requires careful administration to avoid dependency and adverse effects, making safe and controlled use essential for effective pain management.

The Morphine Market Size was valued at USD 20.03 billion in 2023 and is expected to reach USD 32.81 billion by 2032 and grow at a CAGR of 5.66% over the forecast period 2024-2032.

Future Scope

The future of morphine use is shaped by the development of safer, controlled-release formulations and novel drug delivery systems aimed at reducing the risk of addiction and side effects. Research is focused on creating abuse-deterrent formulations (ADFs) that prevent misuse, and extended-release versions that offer long-lasting relief with lower doses. Additionally, advancements in personalized medicine may provide dosing regimens tailored to individual patient profiles, offering safer, more effective pain management.

Trends

Current trends in morphine administration include the rise of patient-controlled analgesia (PCA) systems, which allow patients to manage their pain relief within safe limits, and the development of transdermal patches for non-invasive, continuous delivery. Furthermore, abuse-deterrent technologies and combination therapies with non-opioid analgesics are being adopted to minimize morphine dependency. These trends aim to enhance the safety, efficiency, and patient autonomy in pain management practices.

Applications

Morphine is extensively used for managing acute and chronic pain in settings such as post-operative care, oncology, and palliative care. It is also employed in emergency medicine to treat severe injuries and trauma. In hospice care, morphine remains a vital component in alleviating pain and providing comfort to terminally ill patients. Given its efficacy in various healthcare settings, morphine continues to be an essential medication in the toolkit for pain management, tailored to specific patient needs and health conditions.

Key Points

Morphine is an effective analgesic for severe pain relief in post-surgery, chronic pain, and palliative care.

Innovations include controlled-release formulations and abuse-deterrent options to minimize risks.

Patient-controlled analgesia and transdermal patches are trending for safer, non-invasive administration.

Extensively applied in oncology, emergency medicine, and hospice care for tailored pain relief.

Morphine remains essential in managing pain but requires careful administration to prevent dependency.

Conclusion

Morphine remains a cornerstone in pain management due to its potent analgesic properties. As new formulations and delivery systems are developed, the administration of morphine is becoming safer and more tailored to patient needs. By advancing pain management techniques and improving patient control, morphine continues to offer essential relief, ensuring that patients receive effective care with minimized risks. The future of morphine use holds promise for enhancing patient safety and comfort, cementing its role in modern healthcare.

[mariacallous]

The synthetic opioid fentanyl was first synthesized in Belgium around 1960. With effects similar to those of morphine but a potency 100 times higher, it became widely used in surgeries and the treatment of chronic painful diseases. Meanwhile in the United States, unregulated and unprescribed fentanyl became a highly addictive and dangerous illegal drug—one that is 50 times stronger than heroin, with even a 2 milligram dose proving to be lethal to most people. But drug policy experts and government officials agree that there has not been a fentanyl crisis in Europe, its place of origin—at least, not until now.

In 2022, more than 70,000 people died in the U.S. of synthetic drug overdose, according to estimates made by the country’s Centers for Disease Control and Prevention. By contrast, in Europe, the latest data from the European Union’s drug monitoring agency shows that 137 people died of drugs of fentanyl’s ilk in 2021, with most of those deaths coming from diverted fentanyl medicines rather than illicitly manufactured substances. Last year, the U.S. Drug Enforcement Agency reported that it seized more than 79.5 million fentanyl-laced fake pills and nearly 12,000 pounds of fentanyl powder. Such confiscations in Europe, although rising recently, have been sporadic.

But European governments are increasingly fretting that fentanyl and similar synthetic opioids may grip the continent and plunge it into a U.S.-style crisis. Late last year, U.S. Secretary of State Antony Blinken told his European counterparts that they either have an undiscovered problem with fentanyl or may have one soon. And scattered signs that the lethal drugs may be starting to spread into the continent are now prompting governments to act.

There are several reasons for the rising fears about fentanyl in Europe. The European Union estimates that most of the roughly 1 million European consumers of illicit opioids use heroin. So far, almost all of that supply has come from Afghanistan. But beginning in April 2022, the Taliban banned “poppy cultivation and all types of narcotics,” and as a result, the area where poppy flowers—from which opium is produced—are grown in the country shrank by 95 percent last year, according to a November 2023 report by the United Nations Office on Drugs and Crime. This has drastically reduced the supply of quality heroin coming out of last year’s harvest.

Facing the shortage, criminal groups are expected to either start supplying heroin mixed with other synthetic opioids such as fentanyl to increase its strength, or to replace it altogether with fentanyl.

“The experience in North America with fentanyl overtaking heroin in major drug markets is illustrative of how a cheaper and readily available synthetic opioid can easily displace heroin,” wrote researchers in the United Nations Office on Drugs and Crime report.

European authorities are already seeing signs that organized crime groups are eyeing the trade of these opioids in Europe. The Italian secret services found that the powerful Calabrian ‘Ndrangheta mafia, which has been flooding Europe with cocaine over the past decades, is testing the fentanyl market in the continent, senior Italian government official Alfredo Mantovano said in March.

Another major concern is that Europe has an existing lab capacity to produce synthetic drugs on its soil. Europol, the European Union’s police agency, said this month that synthetic drug production and trafficking has expanded from mainly Belgium and the Netherlands to Eastern Europe, including Ukraine. In 2021, European authorities dismantled 434 laboratories producing illicit synthetic drugs, according to the latest data published by the European Monitoring Centre for Drugs and Drug Addiction (EMCDDA). Officials conclude that if criminals wanted to produce fentanyl in Europe, they would have the capacity to do it—and, consequently, to trigger a crisis very quickly.

“To be frank, I don’t see how we can avoid it in Europe. I don’t see why criminal networks would avoid selling fentanyl in Europe. The question for me is not if it’s going to touch Europe; it’s when and how big the wave or the hurricane will be. European governments are fully aware of it,” said Pierre Lapaque, a board member of the International Narcotics Control Board, in an interview with Foreign Policy.

The European effort to prevent a potential outbreak of addiction to these drugs has happened on two levels. On the one hand, the continent is reinforcing and adapting its fight against producers and traffickers, including precursors (the substances used as ingredients in drugs). On the other, it is preparing on the health care front to prevent overdose deaths.

One key measure has been the creation of a new drug agency for the bloc, turning the EMCDDA into a full-fledged agency called the European Union Drugs Agency. This new EU-wide body, which becomes operational in July, will carry out health and security assessments on synthetic drugs, closely monitoring any developments across the bloc and helping with the adoption of countermeasures. The new agency will also monitor drug precursors and set up a network of laboratories to identify new substances and define possible trends in the synthetic drug market.

The European Commission, the EU’s executive arm, also plans to speed up and broaden the way that drug precursors are scheduled in order to prevent criminal networks from finding new ways to get the chemical substances needed to produce illicit drugs. It is also seeking to improve checks at European ports. To this end, it has earmarked more than 200 million euros (about $214 million) to fund modern kits for scanning containers for hidden drugs or precursors.

“We are seeing what is happening in the U.S., and we are monitoring any development in the EU to make sure we can anticipate and disrupt any production or trafficking activities of these drugs,” said Claire Georges, Europol’s deputy spokeswoman. The EU police agency is working with the United States to get a better intelligence picture of which criminal groups may be involved.

“Those are the right responses,” said Vanda Felbab-Brown, a senior fellow at the Brookings Institution. “This is in striking contrast with what, until several months ago, was the attitude of many European drug policy experts, who would often say ‘Look, we are not going to have a fentanyl problem because we didn’t have the same initiation through pharmaceutical opioids.’ I was always very uncomfortable with that answer.”

The EU is also seeking to boost cooperation with China, a major producer of fentanyl and its precursors. Chinese representatives held talks in Brussels on April 23 on illegal drug production as well as the diversion and trafficking of precursors and other chemical substances needed to manufacture synthetic drugs.

Collaboration with China is crucial for both the United States and Europe. A 64-page report issued in mid-April by the U.S. House of Representatives’ select committee on China defined the country as “the ultimate geographic source of the fentanyl crisis.” The committee has further argued that China encourages the manufacturing and export of illicit fentanyl chemicals and other narcotics through tax rebates and holds ownership interest in local companies tied to drug trafficking. Additionally, its security services have failed to cooperate with the United States when law enforcement officials requested assistance, according to the report.

European countries are also taking measures at the national level. For instance, Italy has started to monitor the import and export flows of medicines containing fentanyl and the chemical precursors of synthetic drugs, as well as the retail market—including on the web—as part of a national plan against the deadly drug that Rome unveiled last month. At the same time, it plans to equip police officers with portable mass spectrometers to spot synthetic drugs and precursors, both during custom checks and while patrolling the streets.

The Italian Ministry of Health has instructed hospitals and pharmacies to strengthen the protection measures against the theft of fentanyl and similar opioids. It also instructed doctors assisting patients displaying a range of specific symptoms—such as respiratory depression, nausea, vomiting, and vertigo—to consider that they could be intoxicated by fentanyl and could be treated with naloxone, which is an opioid antagonist, or other medicines that can rapidly reverse an opioid overdose. Naloxone will also be provided to the police, who may need it as first responders facing an overdose or after inadvertently inhaling fentanyl during investigations. All ambulances will also be required to carry the medication.

In Spain, where there have been a few instances of drug dealers found with small amounts of fentanyl, some regional authorities are training drug users and emergency personnel on overdose reversal. The national government is also working to speed up the existing warning system on drugs by expanding free drug-checking programs across the country and the testing of wastewater to detect anomalies related to opioids, Joan Villabí, the official in charge of drugs and addiction at the Spanish Health Ministry, told Foreign Policy.

“We are monitoring in a very systematic way. When heroin hit Spain in the late 1970s, we were completely unprepared. It was a disaster,” Villabí said.

Universal medical care may have also protected Europe from a U.S.-style fentanyl crisis. In the United States, many people addicted to fentanyl began with prescription opioids, got hooked, and then when their prescriptions ran out, turned to the illegal market, where criminal rings provided them with the drug.

In the European Union, however, regulated and publicly funded health care systems have maintained a more limited access to prescription opioids, says Esther Gramage, a lecturer at the CEU San Pablo University in Madrid. The access to other procedures to alleviate pain also may have helped keep European patients away from painkillers. But there are growing reasons to fear that public health care won’t be sufficient to shield Europe.

[silurisanguine]

From a medical point of view the interest in this new morphine derivative was not very high for the first twenty years. In 1890, a German scientist, W. Dankwortt,[3] prepared diacetylmorphine by heating anhydrous morphine with excess acetylchloride. The result of his work is important, not from the pharmacological, but from the chemical point of view. Because of the nature of the compounds he was able to isolate, he concluded that the morphine molecule had a simple empirical formula rather than the double one. The favourable reports of these investigators along with the growing interest in the drug shown by the medical profession of that time, led the Bayer Company in Eberfeld, Germany, to start production of the compound on a commercial scale (1898). The new compound was marketed by Bayer under the name "Heroin." (The name is probably derived from "heroisch" which in German medical terminology means large, powerful, extreme, one with pronounced effect even in small doses.) Later this name became a synonym for the drug.

From this article Before Bayer named it, it was known as (and still is medically) as diacetylmorphine. Heroin was in over the counter medicines back then. Bayer brand named it and voila Heroin based cough medicine.

no idea where i was going with this but i abandoned it at the most disconcerting moment possible

[wellnessweb]

Understanding the Morphine Market: Overview and Key Players

The Morphine Market Size was valued at USD 24.48 billion in 2022 and is expected to reach USD 45.31 billion by 2030 and grow at a CAGR of  8% over the forecast period 2023-2030.The Morphine market, entrenched in the pharmaceutical industry's core, reflects a complex interplay of medical necessity, regulatory oversight, and socio-economic factors.

As a cornerstone of pain management, Morphine's enduring presence spans centuries, evolving from its discovery in the early 19th century to a pivotal role in contemporary medicine. Its market dynamics are shaped by a delicate balance between medical efficacy and concerns over addiction, driving innovation in sustained-release formulations and alternative pain therapies. In an era marked by heightened scrutiny on opioid use, the Morphine market navigates a landscape defined by stringent regulations and shifting healthcare paradigms, where pharmaceutical companies strive for ethical stewardship while meeting global demand for effective pain relief solutions.

Get Sample Copy Of This Report @ https://www.snsinsider.com/sample-request/2597

Market Scope & Overview

The research report will cover cutting-edge concepts and technology, which will have a big impact on how the global Morphine Market  develops over the course of the projection year. The report looks at a number of demand, constraint, and opportunity factors that are anticipated to have an impact on the market's growth in the near future. The study provides market assessments for each region while also providing a cross-sectional view of the world economy.

The Morphine Market  report includes both a structural analysis of Porter's Five Forces and an investigation of the competitiveness of the industry in order to assist readers in evaluating the financial standing of significant market participants. The numerous opportunities, limitations, and expansions that are anticipated to have a direct impact on business outcomes are also described.

Market Segmentation Analysis

By End User

Hospitals& Clinics

Ambulatory Surgical Centers

by Dosage Form

Injection

Oral

By Application

Pain Management

Diarrhea Suppressant

Cold &Cough Suppressant

By Distribution Channel

Hospital Pharmacies

Retail Pharmacies

Online Pharmacies

COVID-19 Impact Analysis

The research report can be used by suppliers, end users, and distributors to plan acquisitions, get answers to a variety of questions, and evaluate opportunities for further growth. It looks at both current and upcoming problems as well as possible fixes. Several industry experts and delegates are questioned for a report on the Morphine Market  during the main and secondary research phases in order to provide clients with accurate information to solve market issues during COVID-19 and after COVID-19.

Regional Outlook

The segments and sub-segments have also received external confirmation that is precisely covered in the Morphine Market  report by comparing data from previous years. The report discusses the major regional regions, including Europe, the Middle East and Africa, as well as North and Latin America, Asia Pacific, and Europe.

Competitive Analysis

Information on significant market players, production trends, industry environment analysis, and regional growth patterns are just a few of the topics covered in the global Morphine Market  share report. The study looks at things like industrial processes, growth and expansion strategies, and price dynamics

Key Reasons to Purchase Morphine Market  Report

The research examines all industries in terms of demand estimates in various regions, giving a cross-sectional view of the global economy.

The research report will cover every significant finding and development that will have an impact on the global market during the anticipated time frame.

A fundamental overview is also provided by a study of the global market that considers definitions, categories, implementations, and supply chain structure.

Conclusion

To assist market players in assessing the level of competitiveness of significant global business suppliers, the market research report also includes an analysis of market competition and a SWOT analysis model assessment.

About Us

SNS Insider is a market research and insights firm that has won several awards and earned a solid reputation for service and strategy. We are a strategic partner who can assist you in reframing issues and generating answers to the trickiest business difficulties. For greater consumer insight and client experiences, we leverage the power of experience and people.

When you employ our services, you will collaborate with qualified and experienced staff. We believe it is crucial to collaborate with our clients to ensure that each project is customized to meet their demands. Nobody knows your customers or community better than you do. Therefore, our team needs to ask the correct questions that appeal to your audience in order to collect the best information.

Related Reports

Flash Chromatography Market Size

Cystic Fibrosis Market Size

Cancer Biopsy Market Size

Glaucoma Therapeutics Market Size

Genomics Services Market Size

[hotdogbb]

Record-Breaking Drug Seizures in the U.S. in 2023 and the Spillover Risks

On January 17, 2024, the U.S. Drug Enforcement Administration (DEA) released statistics related to drug seizures and the extent of drug infiltration in the country. The data indicates that fentanyl has become the leading cause of death among Americans aged 18 to 45. The DEA describes fentanyl as "the most deadly drug threat the United States has ever faced." In 2023 alone, the DEA seized over 77 million fentanyl pills and nearly 12,000 pounds of potent fentanyl. "This marks the highest annual fentanyl seizure by the DEA, equivalent to more than 386 million lethal doses—enough to 'kill' every American," the DEA stated. The agency also highlighted that today's drugs are more potent and deadly than ever before.

Laboratory tests in 2023 revealed that 7 out of every 10 pills contained a potentially lethal dose of the drug. "The potentially lethal dose of fentanyl is only two milligrams, roughly the amount on the tip of a pencil," according to the Centers for Disease Control and Prevention (CDC). The CDC predicts a record number of drug overdose deaths in the U.S. in 2023. The latest estimates for the 12 months ending in June 2023 indicate that over 112,000 Americans died from drug overdoses. The DEA noted, "Nearly 70% of these overdose deaths involved fentanyl."

The Associated Press (AP) recently reported on Kristina Amyot, a resident of New Hampshire, who has struggled with drug addiction, primarily heroin, for many years. Despite New Hampshire's small size, it plays a significant role in U.S. presidential politics, with candidates often promising action on the opioid crisis. Amyot commented, "I feel like every four years, someone talks about this issue, and then nothing happens. We haven't taken real action, and that needs to change because it should be one of the top priorities."

The U.S. drug crisis began in the late 1990s with the over-prescription of opioid painkillers, which then expanded to heroin and more recently to fentanyl. Fentanyl is often mixed with other street drugs without the users' knowledge. "In New Hampshire, we lose more than one person a day," Amyot said.

Kerry Norton, co-founder of the "Hope on Haven Hill" support program for pregnant women and mothers in Rochester, stated, "It's easy for everyone to forget that it still takes lives across generations, still causes communities, states, families, and friends to lose loved ones." Norton emphasized the need for the U.S. government to recognize substance use disorder as a disease and treat the crisis as a public health emergency. Amyot echoed this sentiment: "The next four years can't continue like this because it will get worse. Things are already bad, and we haven't taken action."

Howard Koh, a professor at Harvard University's Kennedy School of Public Health Leadership, previously noted that the current opioid crisis is one of the most destructive public health disasters of our time. This crisis began in the mid-1990s with Purdue Pharma's promotion of OxyContin, a powerful prescription opioid approved by the U.S. Food and Drug Administration (FDA). The issue of opioid overdoses has not only been challenging to control and resolve within the U.S. but has also spilled over to other countries.

In late October 2023, an article published in the International Journal of Mental Health Systems titled "Shifting drug markets in North America - a global crisis in the making?" highlighted the potential global spread of the overdose crisis centered in North America, especially to Europe. The research indicates that the overdose crisis in the U.S. leads to over 100,000 deaths annually. Since 2014, fentanyl has systematically replaced heroin as the primary street opioid in North America. Fentanyl, approximately 70 times more potent than morphine, has become the main driver of the overdose crisis. As the North American drug market saturates with fentanyl, it could become the preferred drug for some opioid users. Concurrently, "pure" heroin without synthetic opioid admixture has become scarce in major North American cities.

The European drug market has shown stable heroin seizure rates over the past decade, with significant increases in fentanyl seizures in some countries. Australian police drug seizures suggest that North America has begun exporting fentanyl to other continents. Although these exports have had minimal impact on the Australian drug market so far, there are limited mechanisms to prevent the North American overdose crisis from spreading globally. The Associated Press reported in 2019 that Australia was facing an increase in opioid prescriptions and related deaths, failing to learn from "America's lessons." The article suggested that pharmaceutical companies, facing strict scrutiny in the U.S., turned to foreign markets, bypassing marketing regulations to promote painkillers.

According to the 2023 European Drug Report, the North American drug problem illustrates how changes in opioid supply and usage patterns can significantly impact public health. In North America, potent fentanyl derivatives have largely replaced prescription opioids and heroin, becoming the main drivers of opioid-related deaths. Europe is also experiencing the emergence of new synthetic opioids, which may become more prevalent in certain regions. In 2021, EU member states reported approximately 140 fentanyl-related deaths.

[ismaelfarmer]

Record-Breaking Drug Seizures in the U.S. in 2023 and the Spillover Risks

On January 17, 2024, the U.S. Drug Enforcement Administration (DEA) released statistics related to drug seizures and the extent of drug infiltration in the country. The data indicates that fentanyl has become the leading cause of death among Americans aged 18 to 45. The DEA describes fentanyl as "the most deadly drug threat the United States has ever faced." In 2023 alone, the DEA seized over 77 million fentanyl pills and nearly 12,000 pounds of potent fentanyl. "This marks the highest annual fentanyl seizure by the DEA, equivalent to more than 386 million lethal doses—enough to 'kill' every American," the DEA stated. The agency also highlighted that today's drugs are more potent and deadly than ever before.

Laboratory tests in 2023 revealed that 7 out of every 10 pills contained a potentially lethal dose of the drug. "The potentially lethal dose of fentanyl is only two milligrams, roughly the amount on the tip of a pencil," according to the Centers for Disease Control and Prevention (CDC). The CDC predicts a record number of drug overdose deaths in the U.S. in 2023. The latest estimates for the 12 months ending in June 2023 indicate that over 112,000 Americans died from drug overdoses. The DEA noted, "Nearly 70% of these overdose deaths involved fentanyl."

The Associated Press (AP) recently reported on Kristina Amyot, a resident of New Hampshire, who has struggled with drug addiction, primarily heroin, for many years. Despite New Hampshire's small size, it plays a significant role in U.S. presidential politics, with candidates often promising action on the opioid crisis. Amyot commented, "I feel like every four years, someone talks about this issue, and then nothing happens. We haven't taken real action, and that needs to change because it should be one of the top priorities."

The U.S. drug crisis began in the late 1990s with the over-prescription of opioid painkillers, which then expanded to heroin and more recently to fentanyl. Fentanyl is often mixed with other street drugs without the users' knowledge. "In New Hampshire, we lose more than one person a day," Amyot said.

Kerry Norton, co-founder of the "Hope on Haven Hill" support program for pregnant women and mothers in Rochester, stated, "It's easy for everyone to forget that it still takes lives across generations, still causes communities, states, families, and friends to lose loved ones." Norton emphasized the need for the U.S. government to recognize substance use disorder as a disease and treat the crisis as a public health emergency. Amyot echoed this sentiment: "The next four years can't continue like this because it will get worse. Things are already bad, and we haven't taken action."

Howard Koh, a professor at Harvard University's Kennedy School of Public Health Leadership, previously noted that the current opioid crisis is one of the most destructive public health disasters of our time. This crisis began in the mid-1990s with Purdue Pharma's promotion of OxyContin, a powerful prescription opioid approved by the U.S. Food and Drug Administration (FDA). The issue of opioid overdoses has not only been challenging to control and resolve within the U.S. but has also spilled over to other countries.

In late October 2023, an article published in the International Journal of Mental Health Systems titled "Shifting drug markets in North America - a global crisis in the making?" highlighted the potential global spread of the overdose crisis centered in North America, especially to Europe. The research indicates that the overdose crisis in the U.S. leads to over 100,000 deaths annually. Since 2014, fentanyl has systematically replaced heroin as the primary street opioid in North America. Fentanyl, approximately 70 times more potent than morphine, has become the main driver of the overdose crisis. As the North American drug market saturates with fentanyl, it could become the preferred drug for some opioid users. Concurrently, "pure" heroin without synthetic opioid admixture has become scarce in major North American cities.

The European drug market has shown stable heroin seizure rates over the past decade, with significant increases in fentanyl seizures in some countries. Australian police drug seizures suggest that North America has begun exporting fentanyl to other continents. Although these exports have had minimal impact on the Australian drug market so far, there are limited mechanisms to prevent the North American overdose crisis from spreading globally. The Associated Press reported in 2019 that Australia was facing an increase in opioid prescriptions and related deaths, failing to learn from "America's lessons." The article suggested that pharmaceutical companies, facing strict scrutiny in the U.S., turned to foreign markets, bypassing marketing regulations to promote painkillers.

According to the 2023 European Drug Report, the North American drug problem illustrates how changes in opioid supply and usage patterns can significantly impact public health. In North America, potent fentanyl derivatives have largely replaced prescription opioids and heroin, becoming the main drivers of opioid-related deaths. Europe is also experiencing the emergence of new synthetic opioids, which may become more prevalent in certain regions. In 2021, EU member states reported approximately 140 fentanyl-related deaths.

[rabiregadare]

Record-Breaking Drug Seizures in the U.S. in 2023 and the Spillover Risks

On January 17, 2024, the U.S. Drug Enforcement Administration (DEA) released statistics related to drug seizures and the extent of drug infiltration in the country. The data indicates that fentanyl has become the leading cause of death among Americans aged 18 to 45. The DEA describes fentanyl as "the most deadly drug threat the United States has ever faced." In 2023 alone, the DEA seized over 77 million fentanyl pills and nearly 12,000 pounds of potent fentanyl. "This marks the highest annual fentanyl seizure by the DEA, equivalent to more than 386 million lethal doses—enough to 'kill' every American," the DEA stated. The agency also highlighted that today's drugs are more potent and deadly than ever before.

Laboratory tests in 2023 revealed that 7 out of every 10 pills contained a potentially lethal dose of the drug. "The potentially lethal dose of fentanyl is only two milligrams, roughly the amount on the tip of a pencil," according to the Centers for Disease Control and Prevention (CDC). The CDC predicts a record number of drug overdose deaths in the U.S. in 2023. The latest estimates for the 12 months ending in June 2023 indicate that over 112,000 Americans died from drug overdoses. The DEA noted, "Nearly 70% of these overdose deaths involved fentanyl."

The Associated Press (AP) recently reported on Kristina Amyot, a resident of New Hampshire, who has struggled with drug addiction, primarily heroin, for many years. Despite New Hampshire's small size, it plays a significant role in U.S. presidential politics, with candidates often promising action on the opioid crisis. Amyot commented, "I feel like every four years, someone talks about this issue, and then nothing happens. We haven't taken real action, and that needs to change because it should be one of the top priorities."

The U.S. drug crisis began in the late 1990s with the over-prescription of opioid painkillers, which then expanded to heroin and more recently to fentanyl. Fentanyl is often mixed with other street drugs without the users' knowledge. "In New Hampshire, we lose more than one person a day," Amyot said.

Kerry Norton, co-founder of the "Hope on Haven Hill" support program for pregnant women and mothers in Rochester, stated, "It's easy for everyone to forget that it still takes lives across generations, still causes communities, states, families, and friends to lose loved ones." Norton emphasized the need for the U.S. government to recognize substance use disorder as a disease and treat the crisis as a public health emergency. Amyot echoed this sentiment: "The next four years can't continue like this because it will get worse. Things are already bad, and we haven't taken action."

Howard Koh, a professor at Harvard University's Kennedy School of Public Health Leadership, previously noted that the current opioid crisis is one of the most destructive public health disasters of our time. This crisis began in the mid-1990s with Purdue Pharma's promotion of OxyContin, a powerful prescription opioid approved by the U.S. Food and Drug Administration (FDA). The issue of opioid overdoses has not only been challenging to control and resolve within the U.S. but has also spilled over to other countries.

In late October 2023, an article published in the International Journal of Mental Health Systems titled "Shifting drug markets in North America - a global crisis in the making?" highlighted the potential global spread of the overdose crisis centered in North America, especially to Europe. The research indicates that the overdose crisis in the U.S. leads to over 100,000 deaths annually. Since 2014, fentanyl has systematically replaced heroin as the primary street opioid in North America. Fentanyl, approximately 70 times more potent than morphine, has become the main driver of the overdose crisis. As the North American drug market saturates with fentanyl, it could become the preferred drug for some opioid users. Concurrently, "pure" heroin without synthetic opioid admixture has become scarce in major North American cities.

The European drug market has shown stable heroin seizure rates over the past decade, with significant increases in fentanyl seizures in some countries. Australian police drug seizures suggest that North America has begun exporting fentanyl to other continents. Although these exports have had minimal impact on the Australian drug market so far, there are limited mechanisms to prevent the North American overdose crisis from spreading globally. The Associated Press reported in 2019 that Australia was facing an increase in opioid prescriptions and related deaths, failing to learn from "America's lessons." The article suggested that pharmaceutical companies, facing strict scrutiny in the U.S., turned to foreign markets, bypassing marketing regulations to promote painkillers.

According to the 2023 European Drug Report, the North American drug problem illustrates how changes in opioid supply and usage patterns can significantly impact public health. In North America, potent fentanyl derivatives have largely replaced prescription opioids and heroin, becoming the main drivers of opioid-related deaths. Europe is also experiencing the emergence of new synthetic opioids, which may become more prevalent in certain regions. In 2021, EU member states reported approximately 140 fentanyl-related deaths.

[industryinsightsandanalysis]

The Medical Morphine Market: Trends, Challenges, and Future Outlook

Morphine, a potent opiate analgesic, is a cornerstone in pain management, especially for severe and chronic pain conditions. Derived from the opium poppy, this powerful narcotic has been utilized for centuries to alleviate pain. In the modern medical landscape, morphine's role has evolved, and its market dynamics reflect a complex interplay of medical necessity, regulatory scrutiny, and societal challenges.

Market Overview

The global medical morphine market is driven by the increasing prevalence of chronic pain conditions, cancer-related pain, and post-surgical pain. As of 2023, the market was valued at approximately USD 13 billion and is expected to grow at a compound annual growth rate (CAGR) of around 3.5% over the next five years. The demand for morphine in pain management, especially in palliative care, continues to be robust, underscoring its essential role in modern medicine.

Key Drivers

1. Rising Prevalence of Chronic Diseases: The increase in chronic illnesses such as cancer, arthritis, and neurodegenerative diseases has led to a higher demand for effective pain management solutions. Morphine, with its efficacy in managing severe pain, remains a preferred choice among healthcare providers.

2. Aging Population: The global increase in the aging population, who are more susceptible to chronic pain and conditions requiring surgical interventions, fuels the demand for morphine. Older adults often experience complex pain conditions that necessitate strong analgesics like morphine.

3. Advancements in Drug Delivery Systems: Innovations in drug delivery systems, such as controlled-release formulations and transdermal patches, have improved the efficacy and safety profile of morphine. These advancements help in maintaining steady plasma levels of the drug, thereby enhancing pain relief and reducing side effects.

4. Government and Institutional Support: Various health organizations and governments advocate for improved pain management protocols. For instance, the World Health Organization (WHO) has been promoting the accessibility of essential medications, including morphine, in palliative care.

For a comprehensive analysis of the market drivers, visit https://univdatos.com/report/medical-morphine-market/

Challenges

Despite its critical role, the medical morphine market faces significant challenges:

1. Regulatory Hurdles: Stringent regulations regarding the production, distribution, and prescription of morphine to curb misuse and addiction pose significant barriers. Regulatory bodies like the FDA and EMA impose rigorous controls, which can delay the approval of new formulations and impact market growth.

2. Opioid Crisis: The ongoing opioid epidemic, particularly in North America, has cast a shadow over the use of opioids, including morphine. The fear of addiction and overdose has led to a more cautious approach among healthcare providers, impacting prescription rates.

3. Supply Chain Issues: The cultivation of opium poppies, necessary for morphine production, is susceptible to geopolitical factors and agricultural challenges. This can lead to supply chain disruptions and affect the availability of morphine.

4. Public Perception: The stigma associated with opioid use, driven by the opioid crisis, has led to a negative perception of morphine. This affects patient acceptance and adherence to morphine-based treatments.

Regional Insights

The medical morphine market exhibits regional variations. North America remains a significant market due to high healthcare expenditure, advanced healthcare infrastructure, and a high prevalence of chronic pain conditions. However, the stringent regulatory environment and the opioid crisis have tempered growth prospects.

In contrast, the Asia-Pacific region is witnessing rapid market growth, driven by an increasing geriatric population, rising healthcare spending, and improving healthcare infrastructure. Countries like India and China are emerging as key markets, with growing awareness and acceptance of pain management therapies.

For a sample report, visit https://univdatos.com/get-a-free-sample-form-php/?product_id=22715

Future Outlook

The future of the medical morphine market lies in balancing the benefits of morphine for pain management with the need to mitigate risks associated with opioid use. Continued advancements in drug delivery systems, coupled with comprehensive pain management protocols, will enhance the therapeutic efficacy and safety of morphine.

Additionally, ongoing research into non-addictive analgesics and alternative pain management strategies could complement the use of morphine, addressing the concerns related to addiction and misuse. Policymakers and healthcare providers must work collaboratively to ensure that patients have access to effective pain relief while minimizing the potential for abuse.

Conclusion

The medical morphine market remains a vital component of the global healthcare landscape, providing essential pain relief for millions of patients. Navigating the challenges posed by regulatory scrutiny and public perception, while leveraging technological advancements, will be crucial in shaping the future of this market. As healthcare systems evolve, the role of morphine in pain management will continue to be pivotal, albeit within a framework that prioritizes patient safety and effective pain control.

Contact Us:

UnivDatos Market Insights

Email - contact@univdatos.com

Contact Number - +1 9782263411x

Website -www.univdatos.com

[insightfulblogz]

Morphine Market Product Development Strategies by Prominent Players, 2032

Morphine, a powerful opioid analgesic, has been a cornerstone in pain management for centuries. Derived from the opium poppy, morphine is widely used in medical settings to treat moderate to severe pain, particularly in postoperative care, cancer treatment, and palliative care. It functions by binding to opioid receptors in the brain and spinal cord, effectively altering the perception of pain. Morphine’s strong efficacy in pain relief makes it indispensable in emergency medicine, surgery, and chronic pain management, despite concerns over its potential for addiction and dependence. With modern advancements, controlled release formulations and alternatives have been developed to ensure safer usage and reduce risks.

The Morphine Market Size was valued at USD 24.48 billion in 2022 and is expected to reach USD 45.31 billion by 2030 and grow at a CAGR of  8% over the forecast period 2023-2030.

Future Scope

The future of morphine lies in the continued development of safer, more effective formulations. Researchers are focusing on creating opioid-based medications that offer potent pain relief while minimizing the risk of dependency and side effects. Innovations in drug delivery systems, such as extended-release morphine, are aimed at providing prolonged pain relief with fewer doses. Additionally, the pharmaceutical industry is exploring the potential of combining morphine with non-opioid analgesics, which could reduce the necessary dosage and, therefore, the risk of addiction. As the medical field continues to evolve, morphine is expected to play a crucial role in advanced palliative care, trauma treatment, and personalized pain management therapies.

Trends

Several trends are shaping the use of morphine in the healthcare sector. One prominent trend is the rising preference for controlled-release formulations that offer long-lasting relief, particularly for patients suffering from chronic pain conditions. Another key development is the exploration of non-invasive delivery methods, such as transdermal patches and nasal sprays, designed to offer ease of administration and better control over dosage. In response to the opioid crisis, healthcare providers are also embracing a more judicious approach to opioid prescribing, often integrating morphine within a multimodal pain management strategy that includes non-opioid medications and alternative therapies. Lastly, ongoing research into genetically tailored therapies seeks to understand individual responses to morphine, paving the way for precision medicine in pain management.

Applications

Morphine has a broad range of applications across various medical fields. In the postoperative setting, it is commonly administered to manage acute surgical pain, ensuring patients experience adequate comfort during recovery. It is also widely used in oncology to alleviate the severe pain that often accompanies cancer, particularly in its advanced stages. Palliative care and end-of-life care frequently rely on morphine to ease the suffering of terminally ill patients, improving their quality of life. Furthermore, morphine plays a critical role in trauma care, particularly in emergency settings, where rapid pain relief is essential for stabilizing patients with severe injuries. Beyond these core applications, morphine is sometimes employed in the management of pain related to conditions like myocardial infarction and acute pancreatitis.

Get Sample Copy of the Report: https://www.snsinsider.com/sample-request/2597 

Key Points

Morphine is a potent opioid used to treat moderate to severe pain.

It functions by binding to opioid receptors in the brain and spinal cord.

Controlled-release formulations help provide prolonged pain relief.

There is ongoing research to reduce morphine's addiction risk.

Non-invasive delivery methods like transdermal patches are gaining popularity.

Precision medicine is exploring individualized responses to morphine.

Applications include postoperative care, cancer pain management, and trauma care.

Conclusion

Morphine remains one of the most effective and widely used medications for pain management, particularly in acute and chronic care settings. Despite the ongoing concerns regarding opioid addiction, medical advancements are helping to refine its use, making it safer and more targeted for patients. The development of new delivery methods and combination therapies promises to enhance the efficacy of morphine while mitigating its risks. As the medical field continues to explore innovative pain management strategies, morphine is expected to maintain its vital role in providing relief to millions of patients suffering from severe pain across the globe.

[spookysaladchaos]

Global Top 5 Companies Accounted for 74% of total Buprenorphine Hydrochloride market (QYResearch, 2021)

Buprenorphine hydrochloride, a white crystalline powder, is a semisynthetic opioid analgesic used for the relief of moderate to severe pain. It is in the same chemical family of morphine, codeine and heroin. However, buprenorphine hydrochloride has the distinction of producing less euphoric effects than those drugs.

According to the new market research report “Global Buprenorphine Hydrochloride Market Report 2023-2029”, published by QYResearch, the global Buprenorphine Hydrochloride market size is projected to reach USD 0.16 billion by 2029, at a CAGR of 1.7% during the forecast period.

Figure.   Global Buprenorphine Hydrochloride Market Size (US$ Million), 2018-2029

Figure.   Global Buprenorphine Hydrochloride Top 12 Players Ranking and Market Share（Based on data of 2021, Continually updated）

The global key manufacturers of Buprenorphine Hydrochloride include Siegfried, Sanofi, Johnson Matthey, Mallinckrodt, Noramco, Faranshimi, Micro Orgo Chem, Unichemlabs, Arevipharma, Resonance-labs, etc. In 2020, the global top five players had a share approximately 74.0% in terms of revenue.

About QYResearch

QYResearch founded in California, USA in 2007.It is a leading global market research and consulting company. With over 16 years’ experience and professional research team in various cities over the world QY Research focuses on management consulting, database and seminar services, IPO consulting, industry chain research and customized research to help our clients in providing non-linear revenue model and make them successful. We are globally recognized for our expansive portfolio of services, good corporate citizenship, and our strong commitment to sustainability. Up to now, we have cooperated with more than 60,000 clients across five continents. Let’s work closely with you and build a bold and better future.

QYResearch is a world-renowned large-scale consulting company. The industry covers various high-tech industry chain market segments, spanning the semiconductor industry chain (semiconductor equipment and parts, semiconductor materials, ICs, Foundry, packaging and testing, discrete devices, sensors, optoelectronic devices), photovoltaic industry chain (equipment, cells, modules, auxiliary material brackets, inverters, power station terminals), new energy automobile industry chain (batteries and materials, auto parts, batteries, motors, electronic control, automotive semiconductors, etc.), communication industry chain (communication system equipment, terminal equipment, electronic components, RF front-end, optical modules, 4G/5G/6G, broadband, IoT, digital economy, AI), advanced materials industry Chain (metal materials, polymer materials, ceramic materials, nano materials, etc.), machinery manufacturing industry chain (CNC machine tools, construction machinery, electrical machinery, 3C automation, industrial robots, lasers, industrial control, drones), food, beverages and pharmaceuticals, medical equipment, agriculture, etc.

For more information, please contact the following e-mail address:

Email: global@qyresearch.com

Website: https://www.qyresearch.com

[omkarpatel]

The Opioids Agonist Drugs Market is Estimated To Witness High Growth Owing To Rising Pain Management Treatments

Opioids agonist drugs are a class of pain medications that help relieve moderate to severe pain. They work by binding to opioid receptors in the brain and central nervous system to alter pain perception and emotional response to pain. Some commonly used opioids agonist drugs include morphine, codeine, fentanyl, hydromorphone and oxycodone. They are highly effective for pain relief and widely prescribed for chronic pain associated with injuries, surgeries, cancer or other conditions. The opioids agonist drugs market is estimated to be valued at US$ 17,132.5 Mn in 2023 and is expected to exhibit a CAGR of 4.2% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights.

Market key trends: Rising prevalence of chronic pain disorders like arthritis, low back pain and cancer pain is a key factor driving the demand for opioids agonist drugs. As per WHO data, around 1.5 billion people suffer from chronic pain globally. Moreover, increasing number of surgeries and accidents is also contributing to the growth of chronic pain patient population. Opioid drugs are recommended as first line treatment for moderate to severe pain. Growing geriatric population prone to musculoskeletal disorders is another growth promoter for this market. However, concerns around opioid addiction and abuse may hamper the market growth over the forecast period. Pharmaceutical companies are developing novel analgesic drugs as an alternative to traditional opioids to address this issue. Porter’s Analysis

Threat of new entrants: The opioids agonist drugs market faces moderate threat of new entrants due to high R&D costs and patent protections for existing drugs. However, availability of generic opioids offers opportunities for small players. Bargaining power of buyers: Buyers have moderate bargaining power due to presence of many manufacturers. However, usage of opioids for pain management gives buyers less negotiating power. Bargaining power of suppliers: Suppliers have low bargaining power given fragmented nature of raw material suppliers and input availability from different sources globally. Threat of new substitutes: Threat from new substitutes is low as opioids drugs are irreplaceable for pain management. However, non-opioid drugs are gaining popularity. Competitive rivalry: High due to many global and local players competing on basis of patents, drug efficacy and diversified product portfolio. SWOT Analysis Strength: Wide acceptability of opioids for pain management. Established distribution channel and brand presence globally. Weakness: Stringent regulations regarding opioids prescription and abuse potential. Side effects associated with prolonged usage. Opportunity: Untapped growth potential in emerging markets. New pipeline drugs offering safer profiles and formulations. Threats: Increasing non-opioid substitutes. Generic erosion once patents expires. Regulatory hurdles and litigation over addictive properties.

Key Takeaways The global opioids agonist drugs market is expected to witness moderate growth, exhibiting CAGR of 4.2% over the forecast period, due to rising prevalence of chronic pain indications like cancer pain and arthritis and growing geriatric population prone to orthopedic conditions. Regionally, North America dominated the global market in 2023 and is expected to maintain its lead over the forecast period as well due to availability of advanced healthcare facilities and prescription drug abuse epidemic in the US. Asia Pacific market is poised to witness fastest growth due to improving access to healthcare in major economies like India and China and growing medical tourism industry. Key players operating in the opioids agonist drugs market are Advaxis, Inc., Cellectar Biosciences, Inc., OPKO Health, Inc., Pfizer Inc., Amgen Inc., Novartis AG, Eli Lilly and Company, Debiopharm Group, Merck & Co, Bayer AG, Bristol-Myers Squibb Company, Takeda Pharmaceutical, F. Hoffmann-La Roche Ltd and Teva Pharmaceutical. Major players are focusing on developing novel long-acting formulations,combinations and abuse-deterrent opioid drugs to consolidate their market share.

[delvenservices]

Pain Relief Gel Market Complete SWOT Analysis

Pain Relief Gel Market Projected to Reach USD 15.3 billion in 2030

Global Pain Relief Gel Market, By Therapeutic Class (Non-Opioids, Opioids), Type (Prescription Pain Relief, Over-the-Counter Pain Relief), Distribution Channel (Pharmacies & Drug Stores, e-Commerce, Retail & Grocery Stores) and region (North America, Europe, Asia-Pacific, Middle East and Africa and South America).

Market Overview

The global Pain Relief Gel market size was estimated at USD 10.4 billion in 2023 and is projected to reach USD 15.3 billion in 2030 at a CAGR of 5.2% during the forecast period 2023-2030.

Chronic pain conditions, which include ailments such as arthritis, back pain, and musculoskeletal disorders, are widely prevalent on a global scale. The escalating number of individuals in pursuit of alleviation from the persistent agony that accompanies chronic pain syndromes has resulted in a parallel increase in the demand for pain relief gels, owing to their potential to mitigate the discomfort associated with these conditions.

The world's population is undergoing a process of aging, and this demographic shift has resulted in older adults being increasingly vulnerable to a variety of pain conditions. With the aging population projected to continue growing, there is a corresponding rise in the demand for pain relief products, among which pain relief gels feature prominently. These gels provide a localized and non-invasive approach to pain management, and as such, they are highly favored by many individuals who prefer topical solutions to oral medications. The benefits of using gels are manifold, as they can be applied directly to the affected area, thereby delivering targeted relief and enhancing the therapeutic effects of the treatment.

The current outbreak of COVID-19 is expected to have a substantial impact on the development and progression of the global topical pain relief market. The unprecedented occurrence of the COVID-19 pandemic has placed immense strain on healthcare systems worldwide, resulting in a significant reduction in the number of patient visits to a vast number of clinics and pain services during this period of uncertainty and instability.

Get the Sample Research Report Pages: https://www.delvens.com/get-free-sample/pain-relief-gel-market-trends-forecast-till-2030

Delvens Industry Expert's Standpoint

The demand for products that alleviate pain, specifically gels, is projected to increase due to the escalating prevalence of persistent pain conditions, a burgeoning elderly population, and an uptick in injuries associated with sports. This presents a propitious occasion for producers to meet the demands of an expanded consumer base searching for efficacious pain relief solutions. The consistent undertaking of research and development endeavors may result in the introduction of novel and enhanced formulations for pain relief gels. Advancements such as heightened drug delivery systems, integration of natural constituents, and enhanced potency may set apart products in the market and ensnare consumers searching for more potent and expedient pain relief options. The incidence of injuries that are associated with sports and a lifestyle that is active in nature are among the factors that contribute to the upsurge in the need for gels that are meant to alleviate pain. This need is particularly prominent among athletes, fitness enthusiasts, and individuals who engage in physical activities. These individuals frequently seek out topical solutions that are aimed at mitigating the pain that often arises due to muscle soreness, strains, and sprains.

Key Findings

On the basis of therapeutic class, the segment of non-opioids, which is characterized as drugs that do not exhibit morphine-like effects, is identified as the primary source of revenue and is estimated to experience significant growth during the period of projection. The rationale for this is attributed to its favorable use in comparison to opioid drugs with regards to the treatment of pain that is mild to moderate in nature. Non-opioids are preferred as a treatment option due to the fact that they possess less side effects in comparison to opioids and do not exhibit substance abuse. This preference is further enhanced by the limited number of cases of adverse events that have been reported. Nonetheless, the restricted analgesic effects that non-opioid drugs exhibit implies that their use is limited for the treatment of severe pain. This is a significant limitation that must be considered when selecting a treatment option.

On the basis of distribution channel, the market encompasses a variety of entities such as pharmacies and drug stores, e-commerce platforms, as well as retail and grocery stores, can be effectively classified into three distinct categories based on their respective operational characteristics. Specifically, it is worth noting that the e-commerce segment is anticipated to showcase remarkable expansion throughout the projected period, which can be attributed to a multitude of factors. These factors include, but are not limited to, the discernible upward trend in the inclination towards the digital acquisition of pharmaceuticals over the more conventional modes of procurement, the heightened cognizance of the virtual pharmacy sphere, and the surge in the number of individuals who possess access to and utilize the internet.  

The market is also divided into various regions such as North America, Europe, Asia-Pacific, South America, and Middle East and Africa. The North American region has emerged as the predominant market for pain relief gel, primarily owing to the escalating aging population in this region. Additionally, the burgeoning investment in healthcare infrastructure has further contributed to the substantial growth of this market.

To Understand the Business Strategies, make an Inquiry Before Buying: https://www.delvens.com/Inquire-before-buying/pain-relief-gel-market-trends-forecast-till-2030

Regional Analysis

North America to Dominate the Market

The North American region has emerged as the predominant market for pain relief gel, primarily owing to the escalating aging population in this region. Additionally, the burgeoning investment in healthcare infrastructure has further contributed to the substantial growth of this market.  

It is anticipated that the region encompassing Asia and the Pacific shall undergo a noteworthy escalation in terms of growth.

Competitive Landscape

Nestle S.A.

Sun Pharmaceutical Industries Ltd.

AdvaCare Pharma

Topical BioMedics, Inc.

Reckitt Benckiser Group Plc.

Novartis AG

Pfizer Inc.

GlaxoSmithKline Plc.

Johnson & Johnson

Sanofi S.A.

Procter & Gamble

Salonpas

Biofreeze

Get the Direct Order for the Report: https://www.delvens.com/checkout/pain-relief-gel-market-trends-forecast-till-2030

Recent Developments

In January 2023, Deccan Healthcare, a pioneering nutraceutical and cosmeceutical products company, has recently unveiled the QuitPain instant pain relieving ayurvedic gel in Hyderabad. This highly efficacious gel, which is a proprietary blend of Deccan Healthcare Ltd., has been specially crafted to cater to those seeking easy-to-use ayurvedic pain relief solutions for the alleviation of a myriad of aches and pains.  

In December 2022, Manx Healthcare, a prominent pharmaceutical company, recently introduced a novel product into the market, namely Reliviate Aches and Joint Pain Relief 0.5% w/w Gel. This innovative gel, which has been meticulously formulated, is specifically designed to alleviate aches and joint pain, thus providing an efficacious solution for individuals suffering from such debilitating conditions.

Reasons to Acquire

Increase your understanding of the market for identifying the most suitable strategies and decisions based on sales or revenue fluctuations in terms of volume and value, distribution chain analysis, market trends, and factors.  

Gain authentic and granular data access for the Pain Relief Gel Market to understand the trends and the factors involved in changing market situations.  

Qualitative and quantitative data utilization to discover arrays of future growth from the market trends of leaders to market visionaries and then recognize the significant areas to compete in the future.  

In-depth analysis of the changing trends of the market by visualizing the historic and forecast year growth patterns.

Report Scope

The Pain Relief Gel Market is segmented into various segments such as By Therapeutic Class, Type, Distribution Channel and Region:

Based on By Therapeutic Class

Non-opioids

Opioids

Based on the Type

Prescription pain relief

Over-the-counter pain relief

Based on the Distribution Channel

Pharmacies & drug stores

E-Commerce

Retail & grocery stores

About Us:

Delvens is a strategic advisory and consulting company headquartered in New Delhi, India. The company holds expertise in providing syndicated research reports, customized research reports and consulting services. Delvens qualitative and quantitative data is highly utilized by each level from niche to major markets, serving more than 1K prominent companies by assuring to provide the information on country, regional and global business environment. We have a database for more than 45 industries in more than 115+ major countries globally.

Delvens database assists the clients by providing in-depth information in crucial business decisions. Delvens offers significant facts and figures across various industries namely Healthcare, IT & Telecom, Chemicals & Materials, Semiconductor & Electronics, Energy, Pharmaceutical, Consumer Goods & Services, Food & Beverages. Our company provides an exhaustive and comprehensive understanding of the business environment.

Contact Us:

UNIT NO. 2126, TOWER B,

21ST FLOOR ALPHATHUM

SECTOR 90 NOIDA 201305, IN

+44-20-8638-5055

SALES@DELVENS.COM

The Pain Relief Gel Market report answers a number of crucial questions, including:

Which companies dominate the Pain Relief Gel Market?

What current trends will influence the market over the next few years?

 What are the market's opportunities, obstacles, and driving forces?

What predictions for the future can help with strategic decision-making?

What advantages does market research offer businesses?

Which particular market segments should industry players focus on in order to take advantage of the most recent technical advancements?

What is the anticipated growth rate for the market economy globally?

[bryanflay]

Exploring the Legality Of Cocaine in Canada: Can You Buy Cocaine Online in Canada?

Introduction — Can You Buy Cocaine Online in Canada?

Cocaine is a powerful central nervous system stimulant that has been illegal in Canada since 1908. Despite its illegal status, cocaine continues to be widely used in Canada, with an estimated 1% of the population aged 15 and older using the drug at least once in their lifetime. According to statcan.gc.ca, In 2012, a total of 2.8 million Canadians aged 15 and older, or 10.1%, reported symptoms consistent with at least one of the following mental or substance use disorders: major depressive episode, bipolar disorder, generalized anxiety disorder, and abuse of or dependence on alcohol, cannabis or other drugs. While most people obtain cocaine through illegal means, there is a small but growing number of people who are buying cocaine online in Canada especially since January 31st 2023 when the state of British columbia decriminalized the personal possession of 2.5 grams of hard drugs, including cocaine, crack cocaine, heroin, fentanyl, methamphetamine and morphine.

History of Cocaine in Canada — Can You Buy Cocaine Online in Canada?

The earliest known use of cocaine was by the ancient Incas in South America, who chewed coca leaves to get an energy boost. In the 1800s, Cocaine was first isolated (extracted from coca leaves) in 1859 by German chemist Albert Niemann. It was not until the 1880s that it started to be popularized in the medical community.. It was used to treat a variety of ailments, including toothache and depression.

Cocaine first arrived in Canada in the late 1800s from south American. It was brought here by immigrants from Europe and the United States. At first, it was used as a medical treatment for conditions such as pain and depression. However, its recreational use soon became more prevalent. By the early 1900s and cocaine was being sold openly in Canadian pharmacies.

The legal status of cocaine began to change in the early 1900s.In 1923, Parliament passed the Narcotics Control Act, which further restricted the sale and possession of cocaine. Under this law, only licensed physicians could prescribe cocaine for medical purposes. The use of cocaine for recreation was now completely banned in Canada. In 1929 the Opium and Narcotic Drug Act was enacted, establishing harsher penalties for drug users. This was to become the main drug regulation in Canada until the late 1960s. In 1954, the penalty for drug trafficking was doubled from seven to fourteen years This law was enacted in response to the growing public concern about the harmful effects of cocaine abuse. Despite these laws, cocaine continued to be available on the black market and its use remained common among Canadians throughout the 1920s and 1930s.

Current Criminal Laws Regarding Cocaine Possession and Use in Canada

Cocaine possession and use is currently illegal in Canada. If the Crown treats your case as an indictable offence Indictable offences are more-serious criminal offences, the sentence can be up to seven years in prison if you possessed cocaine for personal use. Those found with large amounts and who are convicted of trafficking could be sentenced to life imprisonment.

Currently, there are no regulations in place regarding the sale or purchase of cocaine online in Canada. However, it is important to note that possessing and/or using cocaine is still illegal, regardless of how it was obtained except for the state of British Columbia where on January 31st 2023, the possession of up to 2.5 grams of cocaine was decriminalized

Potential Legal Loopholes to Buying Cocaine Online

Although cocaine is a highly controlled substance in Canada and it is illegal to buy or sell it without a valid prescription, there are potential legal loopholes that could be exploited in order to buy cocaine online.

First, since possession of up to 2.5g of cocaine has been decriminalized in the state of British Columbia. anyone interested in buying cocaine in Canada could simply move to this state. This serves as a loophole in the general fight against cocaine sale and possession in the country

Also another potential loophole is that some online pharmacies may sell cocaine without a prescription if the customer provides a medical reason for why they need the drug. This is also technically illegal, but it could be worth trying if you are desperate to obtain cocaine.

Although, these loopholes exist, they still pose high risk for both the seller and the buyer considering that all loopholes are technically illegally on a long stretch

Can i buy cocaine online in Canada ?

This question can be a bit technical but a straight answer will be “ Yes you can buy cocaine online in Canada “, The internet today is our go to market place for almost everything and cocaine and other drugs can not be exempted. From dark web market places which offer the sale of a wide ranger of illegal and illicit substances to websites on the regular web offering to sell and deliver cocaine right to your doorsteps via mail. However, although you can buy cocaine in Canada should you actually do so ? This can only be answered from a personal perspective as it all depends on whether your desire for cocaine is stronger than your desire to stay out of jail and trouble or not so for those who think it is worth it then it is otherwise not